 Mitomycin adjuvant treatment gastric cancer follow-up Seventy consecutive patients two-arm randomized trial surgical resection advanced gastric cancer first arm patients control group treatment surgery second arm patients adjuvant chemotherapy consisting mitomycin MMC weeks consecutive cycles patients arms way years years patients control arm patients treatment arm dead relapse Actuarial survival curve significant favor patients adjuvant MMC years patients control arm patients treatment arm dead relapse statistical differences actuarial survival curve favor treated patients advantages adjuvant treatment stage frequent relapse site peritoneal cavity relapse pattern special decrease liver metastases treated patients Toxicity acute mild delayed toxicity second malignancies data adjuvant MMC surgery gastric cancer successful treatment effects evident years follow-up